Genetic Variants in Histone Modification Regions Predict Clinical Outcomes of Pemetrexed Chemotherapy in Lung Adenocarcinoma
Open Access
- 18 October 2022
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 101 (2), 96-104
- https://doi.org/10.1159/000527492
Abstract
Objective This study was conducted to investigate the association between genetic variants in histone modification regions and clinical outcomes of PEM chemotherapy in patients with lung adenocarcinoma. Methods Potentially functional SNPs were selected using integrated analysis of ChIP-seq and RNA-seq. The associations of 279 SNPs with chemotherapy response and overall survival (OS) were analyzed in 314 lung adenocarcinoma patients who underwent PEM chemotherapy. Results Among the SNPs investigated, 18 were significantly associated with response to chemotherapy, while 28 with OS. Of these SNPs, rs549794A>G in an enhancer which is expected to regulate the expression of ribosomal protein S3 (RPS3) gene was significantly associated with both worse response to chemotherapy and worse OS (adjusted odds ration [aOR] = 0.59, 95% CI = 0.36-0.97, P = 0.04; adjusted hazard ratio [aHR] = 1.44, 95% CI = 1.09-1.91, P = 0.01, respectively). Previous studies suggested that RPS3, a multi-functional protein with various extraribosomal activities, may play a role in chemotherapy resistance. Therefore, it is postulated that rs549794-induced change in the expression level of RPS3 may affect the response to PEM chemotherapy and consequently the survival outcomes in lung adenocarcinoma patients. Conclusion This study suggests that genetic variants in the histone modification regions may be useful for the prediction of clinical outcomes of PEM chemotherapy in advanced lung adenocarcinoma.Keywords
This publication has 44 references indexed in Scilit:
- Hallmarks of Cancer: The Next GenerationCell, 2011
- How Common Are Extraribosomal Functions of Ribosomal Proteins?Molecular Cell, 2009
- Ultrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Model-based Analysis of ChIP-Seq (MACS)Genome Biology, 2008
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Molecular basis of antifolate resistanceCancer and Metastasis Reviews, 2007
- Hrr25-dependent phosphorylation state regulates organization of the pre-40S subunitNature, 2006
- Human Ribosomal Protein S3 Interacts with DNA Base Excision Repair Proteins hAPE/Ref-1 and hOGG1Biochemistry, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004